NYSE:ABBV - AbbVie Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$98.50 -1.07 (-1.07 %)
(As of 06/18/2018 04:00 PM ET)
Previous Close$99.23
Today's Range$98.31 - $99.33
52-Week Range$69.38 - $125.86
Volume289,297 shs
Average Volume11.97 million shs
Market Capitalization$158.01 billion
P/E Ratio17.59
Dividend Yield3.86%
Beta1.61

About AbbVie (NYSE:ABBV)

AbbVie logoAbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a subcutaneous treatment for relapsing forms of multiple sclerosis. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has a strategic collaboration with Alector, Inc.; C2N Diagnostics; Voyager Therapeutics, Inc.; Janssen Biotech, Inc.; and International Myeloma Foundation. The company was incorporated in 2012 and is based in North Chicago, Illinois.

Receive ABBV News and Ratings via Email

Sign-up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:ABBV
CUSIP00287Y10
Phone847-932-7900

Debt

Debt-to-Equity Ratio8.70
Current Ratio1.20
Quick Ratio1.10

Price-To-Earnings

Trailing P/E Ratio17.59
Forward P/E Ratio12.63
P/E Growth0.93

Sales & Book Value

Annual Sales$28.22 billion
Price / Sales5.54
Cash Flow$6.5146 per share
Price / Cash15.12
Book Value$3.19 per share
Price / Book30.88

Profitability

EPS (Most Recent Fiscal Year)$5.60
Net Income$5.31 billion
Net Margins21.55%
Return on Equity186.47%
Return on Assets14.42%

Miscellaneous

Employees29,000
Outstanding Shares1,586,880,000

AbbVie (NYSE:ABBV) Frequently Asked Questions

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie announced a quarterly dividend on Thursday, June 14th. Stockholders of record on Friday, July 13th will be paid a dividend of $0.96 per share on Wednesday, August 15th. This represents a $3.84 annualized dividend and a dividend yield of 3.90%. View AbbVie's Dividend History.

How will AbbVie's stock buyback program work?

AbbVie declared that its Board of Directors has initiated a stock buyback plan on Friday, February 16th 2018, which authorizes the company to buyback $10,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to reacquire shares of its stock through open market purchases. Stock buyback plans are generally a sign that the company's management believes its shares are undervalued.

How were AbbVie's earnings last quarter?

AbbVie Inc (NYSE:ABBV) released its quarterly earnings results on Thursday, April, 26th. The company reported $1.87 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.79 by $0.08. The firm had revenue of $7.93 billion for the quarter, compared to analysts' expectations of $7.60 billion. AbbVie had a net margin of 21.55% and a return on equity of 186.47%. The company's revenue for the quarter was up 21.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.28 EPS. View AbbVie's Earnings History.

When is AbbVie's next earnings date?

AbbVie is scheduled to release their next quarterly earnings announcement on Friday, July, 27th 2018. View Earnings Estimates for AbbVie.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie issued an update on its FY18 earnings guidance on Thursday, April, 26th. The company provided EPS guidance of $7.66-7.76 for the period, compared to the Thomson Reuters consensus estimate of $7.53.

What price target have analysts set for ABBV?

17 Wall Street analysts have issued 1 year price targets for AbbVie's stock. Their predictions range from $65.61 to $157.00. On average, they expect AbbVie's share price to reach $104.6150 in the next year. View Analyst Ratings for AbbVie.

What are Wall Street analysts saying about AbbVie stock?

Here are some recent quotes from research analysts about AbbVie stock:
  • 1. According to Zacks Investment Research, "AbbVie’s key drug Humira has been performing well based on strong demand trends, despite new competition. Moreover, Imbruvica has multibillion dollar potential and AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases. AbbVie’s shares have outperformed the industry in the past year supported by a series of positive news including promising data from several pivotal studies, regulatory approvals, including its competitive HCV medicine Mavyret and two approvals for Imbruvica and settlement of its Humira patent disputes with Amgen. In fact. Mavyret has become a major growth driver for AbbVie in a short time on the market. Also, several pivotal data readouts and regulatory milestones are expected in 2018. However, Viekira’s sales continue to be hurt by intensifying competition." (3/20/2018)
  • 2. BMO Capital Markets analysts commented, "On its fiscal 3Q18 earnings call, MDT said it does not expect the first-in- human use of its surgical robot in the next couple of months as the company had intended. Recall, MDT had previously said that it expected to be in clinical use by end of its fiscal 2018." (2/15/2018)

Are investors shorting AbbVie?

AbbVie saw a increase in short interest in the month of May. As of May 31st, there was short interest totalling 43,501,770 shares, an increase of 80.5% from the May 15th total of 24,096,693 shares. Based on an average daily trading volume, of 14,776,682 shares, the days-to-cover ratio is presently 2.9 days. Currently, 2.7% of the company's shares are sold short.

Who are some of AbbVie's key competitors?

Who are AbbVie's key executives?

AbbVie's management team includes the folowing people:
  • Mr. Richard A. Gonzalez, Chairman & CEO (Age 64)
  • Mr. William J. Chase, Exec. VP & CFO (Age 50)
  • Mr. Michael E. Severino, Exec. VP of R&D and Chief Scientific Officer (Age 52)
  • Ms. Laura J. Schumacher, Exec. VP of External Affairs, Gen. Counsel & Corp. Sec. (Age 55)
  • Mr. Carlos Alban, Exec. VP of Commercial Operations (Age 55)

Has AbbVie been receiving favorable news coverage?

Press coverage about ABBV stock has been trending somewhat positive this week, Accern reports. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AbbVie earned a media sentiment score of 0.17 on Accern's scale. They also gave news headlines about the company an impact score of 43.87 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Who are AbbVie's major shareholders?

AbbVie's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.30%), Northern Trust Corp (1.36%), Wells Fargo & Company MN (0.80%), Legal & General Group Plc (0.48%), LSV Asset Management (0.39%) and Schwab Charles Investment Management Inc. (0.38%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Carlos Alban, Edward J Rapp, Henry O Gosebruch, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.

Which institutional investors are selling AbbVie stock?

ABBV stock was sold by a variety of institutional investors in the last quarter, including Epoch Investment Partners Inc., Federated Investors Inc. PA, BlackRock Inc., Wells Fargo & Company MN, Prudential Financial Inc., Swiss National Bank, Legal & General Group Plc and Northern Trust Corp. Company insiders that have sold AbbVie company stock in the last year include Azita Saleki-Gerhardt, Carlos Alban, Henry O Gosebruch, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Insider Buying and Selling for AbbVie.

Which institutional investors are buying AbbVie stock?

ABBV stock was bought by a variety of institutional investors in the last quarter, including Summit Trail Advisors LLC, Mackay Shields LLC, Rock Springs Capital Management LP, SG Americas Securities LLC, Dimensional Fund Advisors LP, Caisse DE Depot ET Placement DU Quebec, Franklin Resources Inc. and ING Groep NV. View Insider Buying and Selling for AbbVie.

How do I buy shares of AbbVie?

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AbbVie's stock price today?

One share of ABBV stock can currently be purchased for approximately $98.50.

How big of a company is AbbVie?

AbbVie has a market capitalization of $158.01 billion and generates $28.22 billion in revenue each year. The company earns $5.31 billion in net income (profit) each year or $5.60 on an earnings per share basis. AbbVie employs 29,000 workers across the globe.

How can I contact AbbVie?

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.


MarketBeat Community Rating for AbbVie (ABBV)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  709 (Vote Outperform)
Underperform Votes:  428 (Vote Underperform)
Total Votes:  1,137
MarketBeat's community ratings are surveys of what our community members think about AbbVie and other stocks. Vote "Outperform" if you believe ABBV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABBV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.